IPO Details

IPO Logo
IPO Logo
Avience Biomedicals Ltd
SMEListed
Open:Thu, 18 Jun 2026
Close:Mon, 22 Jun 2026
Lot Size:600 Shares
Price Band:₹ 196 - ₹ 208
Listing:NSE
Fresh Issue:30.24 Cr
OFS:-
Total IPO Size:30.24 Cr
QIB : 50.00%
Retail : 35.00%
Total HNI : 15.00%
EventDate
Open Date18-06-2026 , Thursday
Close Date22-06-2026 , Monday
Tentative Allotment23-06-2026 , Tuesday
Tentative Listing Date25-06-2026 , Thursday
Retail Appl. Cut Off Time22-06-2026 , Monday 05:00 PM
Non Retail Appl. Cut Off Time22-06-2026 , Monday 04:00 PM
Anchor Allotment17-06-2026 , Wednesday
Initiation Of Refund24-06-2026 , Wednesday
Credit Of Share To Demat24-06-2026 , Wednesday

Subscription Data

CategorySize
(In Cr)		Subscribed
(In Cr)		No of Times
(x)
QIB5.691,119.82196.77
bNII (Above 10L)2.871,925.39670.77
sNII (2L to 10L)1.44647.66451.27
NII Total4.312,573.05597.00
Retail10.014,014.17401.06
Total20.017,707.04385.25
CategoryPercentageNo. of Shares OfferedAmount
QIB
50.00 %
6,83,400
14.21 Cr
Retail
35.00 %
4,81,200
10.01 Cr
Total HNI
15.00 %
2,07,000
4.31 Cr
SHNI
5.00 %
69,000
1.44 Cr
BHNI
10.00 %
1,38,000
2.87 Cr
Market Maker
0.00 %
82,200
1.71 Cr

Avience Biomedicals Ltd allotted 4,09,800 equity shares to anchor investors at ₹208 per share on 17 Jun 2026 before the IPO opening. The total anchor allocation stood at 8.52 Cr across 4 anchor investors.

The largest anchor investor received 35.29% of the anchor portion. The top five anchor investors together received 4,09,800 shares, representing about 100.00% of the total anchor allocation.

Top 4 Anchor Investors

RankAnchor Investor NameShares AllocatedAllocation %Allocation Amount
1Sanshi Fund-I1,44,60035.29 %3.01 Cr
2Meru Investment Fund PCC-Cell 11,20,60029.43 %2.51 Cr
3Fortune Hands Growth Fund Scheme I96,00023.43 %2.00 Cr
4Shine Star Build Cap Pvt Ltd48,60011.86 %1.01 Cr

The figures are based on the company’s stock exchange anchor allotment intimation. Anchor allocation is only an informational disclosure and does not indicate future listing performance.

ApplicationDiscountQty (Lot)Total
Retail MIN
-
1200 (2)
₹ 2,49,600
Retail MAX
-
1200 (2)
₹ 2,49,600
SHNI MIN
-
1800 (3)
₹ 3,74,400
SHNI MAX
-
4800 (8)
₹ 9,98,400
BHNI MIN
-
5400 (9)
₹ 11,23,200
ObjectiveNo Of SharesAmount
Fresh Issue
14,53,800
30.24 Cr
DocumentAction
RHPView
Anchor AllotmentView
IPO Contact Details
Registered Office
C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi- 110058, India
Corporate Office
C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi- 110058, India
Contact Person
Manoj Kumar - Company Secretary and Compliance Officer
Registrar to Issue Details
Registrar Name
Skyline Financial Services Private Limited
Contact Person
Anuj Rana

Lead Managers

NameContact PersonTelephoneEmailWebsite
Fintellectual Corporate Advisors
Private Limited
Amit Puri / Pramod Negi
+91-120-4266080
ipo@fintellectualadvisors.com
www.fintellectualadvisors.com
IPO Details

Avience Biomedicals Ltd IPO Details FAQs

Understand company details, IPO size, price band, lot size, exchange listing, fresh issue and Offer for Sale (OFS) in simple language for retail investors.

Which company's IPO is this?

This IPO is of Avience Biomedicals Ltd. The issue is scheduled to open on Thursday, 18 June 2026 and closes on Monday, 22 June 2026.

After the IPO process is completed, the shares are proposed to be listed on NSE.

What is the IPO size?

IPO size means the total amount the company plans to raise through the public issue.

For Avience Biomedicals Ltd IPO, the total issue size is Rs 30.24 crore, consisting of a fresh issue of Rs 30.24 crore.

What is the price band or issue price?

Price band is the price range within which investors can bid for shares in a book-built IPO.

For this IPO, the lower price band is Rs 196 per share and the upper price band is Rs 208 per share.

What is the lot size?

Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.

For Avience Biomedicals Ltd IPO, the minimum application size is 1,200 shares, or 2 lots. At the upper price band of Rs 208 per share, the minimum application amount is Rs 2,49,600. Applications must be made in multiples of 600 shares.

What is Fresh Issue in this IPO?

Fresh Issue means the company issues new shares to investors and receives money from that part of the IPO.

For Avience Biomedicals Ltd IPO, the Fresh Issue size is Rs 30.24 crore. The company can use these funds for purposes mentioned in the IPO documents, such as business growth, repayment of borrowings, working capital, capital expenditure, or general corporate purposes.

IPO Timeline

Avience Biomedicals Ltd IPO Timeline FAQs

Understand the important IPO dates, allotment process, refund schedule and listing timeline in a retail-friendly format.

What is the IPO opening date?

The IPO opening date is the first day on which investors can apply for the public issue.

For Avience Biomedicals Ltd IPO, the IPO opens on Thursday, 18 June 2026.

What is the IPO closing date?

The IPO closing date is the last day on which investors can submit, modify, or cancel their IPO applications.

Avience Biomedicals Ltd IPO closes on Monday, 22 June 2026.

When is the tentative allotment date?

The tentative allotment date is the expected date on which the registrar finalizes the share allotment for valid IPO applications.

For Avience Biomedicals Ltd IPO, the tentative allotment date is Tuesday, 23 June 2026.

When is the tentative listing date?

The tentative listing date is the expected date on which IPO shares begin trading on the stock exchanges.

Avience Biomedicals Ltd IPO is expected to list on Thursday, 25 June 2026.

When do refunds and demat credit happen?

After allotment, funds are unblocked or refunds are initiated for non-allotted investors, while allotted shares are credited to investors' demat accounts before listing.

For Avience Biomedicals Ltd IPO, refund initiation is expected on Wednesday, 24 June 2026, and credit of shares to demat accounts is expected on Wednesday, 24 June 2026.

IPO Structure

Avience Biomedicals Ltd IPO Structure FAQs

Understand IPO category-wise reservation, QIB quota, retail quota, HNI allocation, shareholder reservation and the meaning of structure columns in a simple format.

What is the IPO structure?

IPO structure shows how shares are divided among different categories of investors, such as QIB, Retail, NII/HNI, Employees, and Shareholders.

For Avience Biomedicals Ltd IPO, the available categories in the structure table include QIB, Retail, Non-Institutional Investors (NII/HNI), Market Maker. The NII/HNI category includes SHNI and BHNI sub-categories. Investors can use this table to understand category-wise allocation before applying.

What is the QIB category?

QIB stands for Qualified Institutional Buyers. This category includes mutual funds, banks, insurance companies, and other large financial institutions.

In Avience Biomedicals Ltd IPO, 50% shares are reserved under the QIB category, with 6,83,400 shares offered, and an allocation amount of ₹14.21 crore.

What is the Retail category?

The Retail category is reserved for individual investors and HUFs applying within the SME retail application limit, which is generally up to 2 lots under IPO rules.

In Avience Biomedicals Ltd IPO, 35% shares are reserved under the Retail category, with 4,81,200 shares offered, and an allocation amount of ₹10.01 crore.

What is the NII/HNI category?

NII/HNI stands for Non-Institutional Investors / High Net-Worth Individuals. This category generally includes investors applying for more than Rs 2 lakh, above the retail investment limit.

In Avience Biomedicals Ltd IPO, 15% shares are reserved under the NII/HNI category, with 2,07,000 shares offered, and an allocation amount of ₹4.31 crore.

What is the SHNI category?

SHNI stands for Small HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 2 lakh but not exceeding Rs 10 lakh.

In Avience Biomedicals Ltd IPO, 5% shares are reserved under the SHNI sub-category, with 69,000 shares offered, and an allocation amount of ₹1.44 crore.

What is the BHNI category?

BHNI stands for Big HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 10 lakh.

In Avience Biomedicals Ltd IPO, 10% shares are reserved under the BHNI sub-category, with 1,38,000 shares offered, and an allocation amount of ₹2.87 crore.

What is the Market Maker category?

Further in Avience Biomedicals Ltd IPO, Market Maker is one of the categories available in the IPO structure, if applicable.

In Avience Biomedicals Ltd IPO, with 82,200 shares offered, and an allocation amount of ₹1.71 crore.

Investors should read the offer documents for more details about this category.

Lot Size Details

Avience Biomedicals Ltd IPO Lot Size FAQs

Understand retail lot size, HNI application limits, employee category, shareholder category and investment amount calculations using the IPO lot table.

What is lot size in an IPO?

Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.

For Avience Biomedicals Ltd IPO, the minimum application size is 1,200 shares, or 2 lots. At the upper price band of Rs 208 per share, the minimum application amount is Rs 2,49,600. Applications must be made in multiples of 600 shares.

What is Retail minimum application?

Retail minimum application shows the minimum application size for retail investors.

For Avience Biomedicals Ltd IPO, the Retail minimum application is 1,200 shares (2 lots) for about Rs 2,49,600.

What is Retail maximum application?

Retail maximum application shows the maximum application size generally available under the retail category.

For Avience Biomedicals Ltd IPO, the Retail maximum application is 1,200 shares (2 lots) for about Rs 2,49,600.

What is SHNI minimum application?

SHNI minimum application shows the minimum application size for the Small HNI category.

For Avience Biomedicals Ltd IPO, the SHNI minimum application is 1,800 shares (3 lots) for about Rs 3,74,400.

What is SHNI maximum application?

SHNI maximum application shows the maximum application size available under the Small HNI category, when provided.

For Avience Biomedicals Ltd IPO, the SHNI maximum application is 4,800 shares (8 lots) for about Rs 9,98,400.

What is BHNI minimum application?

BHNI minimum application shows the minimum application size for the Big HNI category.

For Avience Biomedicals Ltd IPO, the BHNI minimum application is 5,400 shares (9 lots) for about Rs 11,23,200.

Financial Highlights

Avience Biomedicals Ltd IPO Financial FAQs

Understand important financial figures in simple language using the financial statement data available for the IPO.

What are Financial Highlights?

Financial Highlights show important numbers from the company's financial statements. These may include income, expenses, profit, assets, liabilities, cash flow and other financial information, depending on the data available for the IPO.

The table displays available financial data based on the IPO information currently available. Fields may differ from company to company depending on disclosures and reporting format.

How should investors read the Financial Highlights table?

Investors should read the table to understand the company's financial performance and financial position over different periods.

The table may help users review income, expenses, profitability, balance sheet position, cash movement or other financial information, depending on the available data.

Why can financial line items differ between IPOs?

Financial statement line items may differ because companies operate in different industries and may follow different reporting formats.

Some companies may provide detailed financial breakup, while others may present broader financial categories.

What should investors check in financial data?

Investors should review income, expenses, profitability, debt position, asset base, liabilities and cash flow position together.

A single financial figure should not be used alone to judge the company.

Why is profit not enough to judge an IPO?

Profit is important, but it does not show the full financial picture.

Investors should also review revenue quality, expenses, debt, assets, liabilities, cash flow, valuation and business risks.

Why is cash flow important in financial analysis?

Cash flow helps investors understand how money moves in and out of the business.

A company may report profit but still face cash flow pressure, so cash flow should be reviewed along with profit, debt and balance sheet information.

Should investors rely only on Financial Highlights?

No. Financial Highlights are useful, but investors should also review valuation, peer comparison, KPI data, business risks, IPO pricing, management discussion and official offer documents such as the RHP or DRHP.

Peer Comparison

Avience Biomedicals Ltd IPO Peer Comparison FAQs

Understand how the company may be compared with similar businesses using the peer comparison data available for the IPO.

What is Peer Comparison?

Peer Comparison means comparing the IPO company with businesses operating in a similar sector or industry.

It helps investors understand the company in a broader industry context.

Why is Peer Comparison useful?

Peer Comparison helps investors understand how the company can be compared with similar businesses using available financial or valuation metrics.

It is useful for context, but it should not be treated as a final investment conclusion.

Why can peer comparison metrics differ?

Peer comparison metrics may differ depending on the companies selected, accounting format, business model and available public information.

Investors should compare only relevant and similar metrics.

How should investors read a Peer Comparison table?

Investors should use the peer comparison table as a reference point.

Available metrics should be read together with business model, scale, profitability, margins, debt, growth, valuation and IPO pricing.

Can Peer Comparison decide whether an IPO is good or bad?

No. Peer Comparison does not directly decide whether an IPO is good or bad.

It only provides context for comparison. Final analysis should include financial statements, KPI data, valuation, risk factors and official offer documents.

Should investors rely only on Peer Comparison?

No. Peer Comparison is only one part of IPO analysis.

Investors should also review financial statements, KPI data, business risks, valuation, IPO pricing and company fundamentals.

Key Performance Indicators

Avience Biomedicals Ltd IPO KPI FAQs

Understand important KPI metrics in simple language using the key performance indicator data available for the IPO.

What are Key Performance Indicators (KPIs)?

Key Performance Indicators, or KPIs, are financial and valuation metrics used to understand profitability, efficiency, leverage, return-based ratios and earnings performance.

They help investors understand the company beyond basic financial figures.

Why are KPIs important for IPO investors?

KPIs help investors assess profitability, capital efficiency, leverage, valuation and earnings quality.

They should be reviewed together with financial statements, peer comparison and IPO pricing.

Why can KPI availability differ between IPOs?

KPI data may differ depending on the company, industry, financial disclosures and available offer document information.

Not every IPO may provide every KPI, and some metrics may not be applicable to every business.

How should investors read KPI metrics?

Investors should read KPI metrics together instead of relying on one ratio.

A single KPI may not give the full picture unless it is reviewed with financial statements, peer comparison, business model and valuation.

Can high or low KPI values directly decide investment quality?

No. High or low KPI values need context.

The meaning of a ratio may differ depending on industry, business model, debt level, growth stage, profitability and IPO valuation.

Should investors rely only on KPI data?

No. KPI data is useful, but it should not be used alone.

Investors should also review financial statements, peer comparison, business risks, valuation, IPO pricing and official offer documents such as the RHP or DRHP.